Dr. Edda Spiekerkoetter is a Professor in the Division of Pulmonary and Critical Care at Stanford University and Staff Physician at Stanford Hospital and Clinics. The limited treatment options for patients with end-stage pulmonary arterial hypertension (PAH) and right heart failure that Dr. Spiekerkoetter observed as a Pulmonary and Critical Care fellow at Hannover Medical School in Germany in the early 2000s were the reason she sought out basic research training in vascular biology under the mentorship of Dr. Marlene Rabinovitch at Stanford University.
As a physician scientist, Dr. Spiekerkoetter strives to better understand the pathogenesis and underlying pathobiology of pulmonary and cardiovascular diseases such as PAH, arteriovenous malformations in hereditary hemorrhagic telangiectasia (HHT) and right heart failure to develop more effective treatments for these diseases. Her group uses 3-D deep tissue imaging, mouse mutants and lineage tracing approaches to answer questions about the molecular and anatomic structure of blood vessels in concert with the extracellular matrix in the lung and the heart in health and disease.
A particular focus in the Spiekerkoetter Laboratory is the involvement of the BMPR2/TGF-b pathway in vascular biology. They use High-Throughput Screening techniques, induced pluripotent stem cells and bioinformatic approaches to identify and test repurposed and repositioned drugs that modulate BMPR2 signaling. By testing compounds in vitro and in vivo models of HHT and PAH, their ultimate goal is to identify candidates that would be promising to move forward into clinical trials.
The lab's discoveries have led to the initiation of a phase II clinical trial to test the safety, tolerability and efficacy of low-dose FK506 in PAH at Stanford as well as three patents for repurposed and repositioned drugs for the treatment of PAH and HHT.
Dr. Spiekerkoetter's laboratory values close collaboration of clinicians, translational as well as basic scientists to apply biological concepts to disease models, driven by the notion that they first need to understand processes in health and disease before we can intervene. The ultimate objective of the lab is to successfully realize bench-to-bedside research for their patients.